BRCA Testing, Not Mastectomies, Up After Angelina Jolie Editorial

Share this content:
<i>BRCA</i> Testing, Not Mastectomies, Up After Angelina Jolie Editorial
BRCA Testing, Not Mastectomies, Up After Angelina Jolie Editorial

FRIDAY, Dec. 16, 2016 (HealthDay News) -- After actress Angelina Jolie's 2013 New York Times editorial that announced her preventive double mastectomy, there was an increase in the number of women who were tested for the BRCA genes but no corresponding increase in mastectomy rates, according to research published in the Christmas 2016 issue of the The BMJ.

Sunita Desai, Ph.D., a fellow in the department of health care policy at Harvard Medical School in Boston, and her colleague Anupam Jena, M.D., Ph.D., an associate professor of health care policy at Harvard, collected data on 9,532,836 U.S. women aged 18 to 64. The researchers then analyzed rates of BRCA testing and mastectomies before and after Jolie's editorial appeared in May 2013.

Testing rates rose from 0.71 per 100,000 women in the 15 business days before the editorial ran, to 1.13 per 100,000 women in the 15 business days after the editorial ran. This was an absolute daily increase of 0.45 tests per 100,000 women, the researchers found. The year before, BRCA test rates remained basically unchanged during the same time period.

"Overall mastectomy rates remained unchanged in the months after publication, but 60 day mastectomy rates among women who had a BRCA test fell from 10 percent in the months before publication to 7 percent in the months after publication, suggesting that women who underwent tests as a result of the editorial had a lower pre-test probability of having the BRCA mutation than women tested before the editorial," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »